Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Trodelvy improved PFS by 34% in heavily pre-treated patients

<< Previous

Bullboard Posts

Next >>

Comment by westcoast1000on Jun 18, 2023 3:36pm

142 Views

Post# 35502596

RE:RE:RE:RE:RE:Trodelvy improved PFS by 34% in heavily pre-treated patients

And already Trodelvy is now marketed and heralded in the NYT as part of the breakthrough underway.

I do not think we will be lanquishing and waiting for a long time before we see progress on the regulatory front, on the partnership front, and then on the share price.

Our time is coming fast.

<< Previous

Bullboard Posts

Next >>

High-growth stock Happy Belly opens first Rosie's Burgers in Alberta